Company news
Cognition Therapeutics, Inc. (NASDAQ:CGTX) news
Every Cognition Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit
July 13, 2026
Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting ...
June 24, 2026
Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) T...
June 16, 2026
Cognition Therapeutics Participating in Upcoming Investor Conferences
June 1, 2026
Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis
May 21, 2026
Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Demen...
May 14, 2026
Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update
May 7, 2026
Cognition Therapeutics to Present at Needham Virtual Healthcare Conference
April 7, 2026
Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update
March 26, 2026
Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results
March 23, 2026
Cognition Therapeutics Presents Evidence of Zervimesine’s Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026
March 17, 2026
Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis
March 2, 2026
Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
February 5, 2026
Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies
January 27, 2026
Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine’s Potential to Slow the Progression of Dementia with Lewy B...
January 6, 2026
Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
December 3, 2025
Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (C...
December 1, 2025
Cognition Therapeutics to Participate in 37th Annual Piper Sandler Healthcare Conference
November 20, 2025
Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer’s Disease
November 13, 2025
Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs
November 6, 2025
Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Reaches 75% Enrollment Target
September 3, 2025
Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preemine...
September 2, 2025
Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common Stock
August 27, 2025
Cognition Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
August 26, 2025
Cognition Therapeutics Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine ...
August 12, 2025
Cognition Therapeutics Reports Financial Results for the Second Quarter 2025 and Highlights Progress Across Clinical Programs
August 7, 2025
Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies ...
July 29, 2025
Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine’s Protection of Neurons and Synapses in Alzheimer’s Disease
July 21, 2025
Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Present...
July 16, 2025
Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer’s Disease
July 10, 2025
Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Surpasses 50% Enrollment Target
July 1, 2025
Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer’s Disease and Dementia with Lewy Bodies (DLB)
June 25, 2025
Philanthropic Donor Funds Cognition Therapeutics’ Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
June 3, 2025
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Studying the Patient/Caregiver Lived Experience in Dementia with ...
May 28, 2025
Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health
May 9, 2025
Cognition Therapeutics Reports Topline Results Showing Oral Zervimesine (CT1812) Reduced Lesion Growth in Phase 2 Study in Geographic Atr...
May 8, 2025
Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update
May 7, 2025
Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer’s Disease Processes
April 1, 2025
Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer’s Disease in Podium Presentatio...
March 25, 2025
Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update
March 20, 2025
Cognition Therapeutics to Report Fourth Quarter and Full Year 2024 Results
March 13, 2025
Cognition Therapeutics Granted Extension to Meet Nasdaq Minimum Bid Price Requirement for Continued Exchange Listing
March 12, 2025
Cognition Therapeutics to Present at Life Sciences Virtual Investor Conference
March 10, 2025
Cognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMD
February 27, 2025
Cognition Therapeutics Successfully Passes Pre-defined Futility Analysis of Phase 2 Study of Oral Zervimesine (CT1812) in Geographic Atrophy
February 26, 2025
Cognition Therapeutics’ VP of Research Co-hosting Precision Medicine Workshop at the Neuroimmunology Drug Development Summit
February 25, 2025
Cognition Therapeutics Announces Publication of Commercial Manufacturing Process for Lead Alzheimer’s Candidate, Zervimesine (CT1812)
February 20, 2025
Cognition Therapeutics Presents Phase 2 Results For Drug To Fight DLB At International Conference
February 6, 2025
Cognition’s Positive Phase 2 ‘SHIMMER’ Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Pre...
January 30, 2025
Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences
January 8, 2025